Lexicon Pharmaceuticals | LXRX - Sales Revenues


Lexicon Pharmaceuticals reported $5.49M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.16B 300M Mar/2026
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Illumina USD 1.16B 80M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Ironwood Pharmaceuticals USD 47.71M 74.35M Dec/2025
J&J USD 24.1B 500M Mar/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
MannKind USD 111.96M 29.83M Dec/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Novartis USD 13.86B 50M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Thermo Fisher Scientific USD 12.21B 1.09B Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024